JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Euvrard, C.
Right arrow Articles by Boissier, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Euvrard, C.
Right arrow Articles by Boissier, J. R.

Antidopaminergic effect of estrogens at the striatal level

C Euvrard, C Oberlander and JR Boissier

The present study investigates the possibility that a potent synthetic estrogen (moxestrol) possesses an antidopaminergic effect at the striatal level. Moxestrol and other estrogens, but not progestagens, androgens or corticosteroids, blocked the apomorphine-induced increase in striatal acetylcholine (ACh) levels. This effect required the repeated administration of moxestrol to develop and lasted for at least 24 hr after the final moxestrol injection. Moxestrol-treatment alone did not alter striatal ACh levels nor did it affect striatal choline acetyltransferase or acetylcholinesterase activities. This estrogen did not modify either the basal or the apomorphine-induced decrease in striatal dopamine turnover. In rats with a unilateral 6-OHDA lesion of the nigro-striatal dopamine pathway, moxestrol antagonized the contralateral circling elicited by apomorphine. The effect of moxestrol on the apomorphine-induced increase in striatal ACh levels was abolished by hypophysectomy and mimicked by pituitary transplants under the renal capsule. These findings, together with previous clinical and pharmacological observations, strongly support the hypothesis that moxestrol exerts an antidopaminergic effect at the striatal level by decreasing dopaminergic postsynaptic transmission via mediation of the pituitary gland.

Volume 214, Issue 1, pp. 179-185, 07/01/1980
Copyright © 1980 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 PsychosomaticsHome page
M. T. Wright
Antiemetics, Akathisia, and Pregnancy
Psychosomatics, December 1, 2007; 48(6): 461 - 466.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
R. S. Bridges and E. M. Byrnes
Reproductive Experience Reduces Circulating 17{beta}-Estradiol and Prolactin Levels during Proestrus and Alters Estrogen Sensitivity in Female Rats
Endocrinology, May 1, 2006; 147(5): 2575 - 2582.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. Manconi, V. Govoni, A. De Vito, N. T. Economou, E. Cesnik, I. Casetta, G. Mollica, L. Ferini-Strambi, and E. Granieri
Restless legs syndrome and pregnancy
Neurology, September 28, 2004; 63(6): 1065 - 1069.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
K.-L. Tsang, S.-L. Ho, and S.-K. Lo
Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations
Neurology, June 27, 2000; 54(12): 2292 - 2298.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
P. J. Blanchet, J. Fang, K. Hyland, L. A. Arnold, M. M. Mouradian, and T. N. Chase
Short-term effects of high-dose 17{beta}-estradiol in postmenopausal PD patients: A crossover study
Neurology, July 1, 1999; 53(1): 91 - 91.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1980 by the American Society for Pharmacology and Experimental Therapeutics.